BRCA1 and breast neoplasm: These features are all associated with more aggressive tumour growth and worse prognosis [[19], [20], [21], [22]], and therefore chemotherapy is likely more effective in BRCA1 mutation carriers (and by extension in the prevention of secondary breast tumours, having similar characteristics, at least in our dataset).